<DOC>
	<DOCNO>NCT00618995</DOCNO>
	<brief_summary>The purpose study evaluate potential effect ER niacin/laropiprant , ER niacin , laropiprant , placebo course seven day urinary level specific metabolite ( marker vivo platelet reactivity ) .</brief_summary>
	<brief_title>A Study Evaluate Effects ER Niacin/Laropiprant , Laropiprant , ER Niacin , Placebo Urinary Prostanoid Metabolites ( 0524A-079 ) ( COMPLETED )</brief_title>
	<detailed_description>Subjects receive 1 4 treatment per period eventually receive 4 treatment : Treatment A : ER niacin 2g/laropiprant 40 mg daily + Placebo laropiprant 7 day Treatment B : ER niacin 2 g daily + Placebo laropiprant 7 day Treatment C : laropiprant 40 mg daily + Placebo ER niacin/laropiprant 7 day Treatment D : placebo daily 7 day . There least 7-day interval dose Day 7 period dose Day 1 subsequent period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Female subject may pregnant and/or agree use appropriate method contraception begin least 2 week prior administration first dose study drug first treatment period , throughout study least 2 week administration last dose study drug last treatment period Subject history T2DM either treat diet exercise alone metformin sulfonylurea Subject judge good health ( history Type 2 diabetes mellitus ) base medical history , physical examination , vital sign measurement , laboratory safety test perform prestudy ( screen ) visit and/or prior administration initial dose study drug Subject clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug Subject nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month ; subject discontinue smoke use nicotine/nicotine contain product least approximately 3 month may enrol study discretion investigator Subject mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 10 year Subject history stroke , chronic seizure , major neurological disorder Subject history clinically significant endocrine ( except Type 2 diabetes mellitus ) , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Subject history neoplastic disease ( include leukemia , lymphoma , malignant melanoma ) , myeloproliferative disease , regardless time since treatment Subject history blood platelet related disorder include prior deep venous thrombosis . Subject treat coumadin , heparin , clopidogrel use agent within 2 week screen . Subject treat aspirin use agent within 3 week prior administration screen Subject unable refrain anticipates use medication ( exception metformin sulfonylurea agent ) , include prescription nonprescription drug herbal remedy begin approximately 2 week poststudy visit . No concomitant medication may take study Subject consume excessive amount alcohol , define great 3 glass alcoholic beverage , per day Subject consume excessive amount , define great 6 , coffee , tea , cola , caffeinated beverage per day Subject major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit Subject history significant multiple and/or severe allergy , anaphylactic reaction significant intolerability prescription nonprescription drug food Subject use insulin , PPAR gamma agonist ( rosiglitazone pioglitazone ) , exenatide ( Byetta ) , acarbose ( Prandase , Precose ) dipeptidylpeptidase 4 ( DPP4 ) inhibitor ( JANUVIAâ„¢1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>